Divilabs Rating
JEFFERIES ON DIVI'S LABS : 31.05.2021
* MAINTAIN BUY TARGET: 4,732
* Jefferies maintains Buy call on Divi's Labs
* EBITDA Impacted By COVID Incentive Payments Of *34 Cr
* It's Operationalised 180 Cr Capex Of Total 250 Cr Incurred Since 2018
GOLDMAN SACHS ON DIVI'S LABS : 31.05.2021
* MAINTAIN BUY TARGET: 4,530
* GS has a Buy rating on Divi's Labs, raises target to Rs 4,530 from Rs 4,440/sh
* Q4 Beat; Multiple Drivers To Support Business In FY22
* Market Share Gains On Molecules Like Carbidopa, Levodopa, Valsartan, Mesalamine
* Additional Supply Opportunity For Molnuparivir API To Indian Cos
* Preparing To Raise Market Share In Contrast Media APIs
MOTILAL OSWAL ON DIVI'S LABS : 31.05.2021
* Maintain BUY, Target at Rs 4,850/share
* Better sales growth & superior product mix led to strong earnings growth
* Have raised our FY22E/FY23E EPS estimate by 4%
* Expect a 32% earnings CAGR over FY21-23E
